ArticleBJUI compass2025
Real-world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PSMA PET/CT improves precision diagnosis, treatment, and clinical decision-making in prostate cancer.American journal of translational research · 2026Review
- Real-world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience.BJUI compass · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This work aimed to report real-world outcomes from the use of SBRT to treat ADT naïve, PSMA-detected oligometastatic prostate cancer (OPCa) and to assess disease and treatment characteristics in this heterogeneous population intersect or impact treatment response. Subjects and Methods: This retrospective single-institution study examined PSMA-PET-detected oligometastases ( Results: Sixty-seven patients treated from January 2019 to August 2024 were analysed with a median follow-up of 18.8 months. Ninety-three oligometastatic lesions were treated; 55.3% were treated for nodal disease, 38.8% bone and 5% with lung disease. All lesions were PSMA-detected with median SUVmax 6.3. Median bPFS was 22.1 m; TTNI was 28.8 m. Lower initial T stage and longer duration from OPCa diagnosis to MDT were associated with prolonged bPFS. Lower T stage and PSA doubling time >3 m at MDT were associated with prolonged time to PSA progression. Median PSA fall was 68.9%; PSA 50% response was observed in 55.2%. Twenty-nine patients (43%) had a complete metabolic response after MDT. Median ADT-free survival was not reached. Conclusions: MDT in PSMA-PET-detected OPCa can provide clinically meaningful disease control in a subset of patients. This study supports this approach but warrants continued prospective study and exploration into the castrate-resistant setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.